Cargando…
Post-COVID dyspnea: prevalence, predictors, and outcomes in a longitudinal, prospective cohort
BACKGROUND: The pathophysiology, evolution, and associated outcomes of post-COVID dyspnea remain unknown. The aim of this study was to determine the prevalence, severity, and predictors of dyspnea 12 months following hospitalization for COVID-19, and to describe the respiratory, cardiac, and patient...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008721/ https://www.ncbi.nlm.nih.gov/pubmed/36907855 http://dx.doi.org/10.1186/s12890-023-02376-w |
_version_ | 1784905821444898816 |
---|---|
author | Grewal, Japnam S. Carlsten, Christopher Johnston, James C. Shah, Aditi S. Wong, Alyson W. Ryerson, Christopher J. |
author_facet | Grewal, Japnam S. Carlsten, Christopher Johnston, James C. Shah, Aditi S. Wong, Alyson W. Ryerson, Christopher J. |
author_sort | Grewal, Japnam S. |
collection | PubMed |
description | BACKGROUND: The pathophysiology, evolution, and associated outcomes of post-COVID dyspnea remain unknown. The aim of this study was to determine the prevalence, severity, and predictors of dyspnea 12 months following hospitalization for COVID-19, and to describe the respiratory, cardiac, and patient-reported outcomes in patients with post-COVID dyspnea. METHODS: We enrolled a prospective cohort of all adult patients admitted to 2 academic hospitals in Vancouver, Canada with PCR-confirmed SARS-CoV-2 during the first wave of COVID between March and June 2020. Dyspnea was measured 3, 6, and 12 months after initial symptom onset using the University of California San Diego Shortness of Breath Questionnaire. RESULTS: A total of 76 patients were included. Clinically meaningful dyspnea (baseline score > 10 points) was present in 49% of patients at 3 months and 46% at 12 months following COVID-19. Between 3 and 12 months post-COVID-19, 24% patients had a clinically meaningful worsening in their dyspnea, 49% had no meaningful change, and 28% had a clinically meaningful improvement in their dyspnea. There was worse sleep, mood, quality of life, and frailty in patients with clinically meaningful dyspnea at 12 months post-COVID infection compared to patients without dyspnea. There was no difference in PFT findings, troponin, or BNP comparing patients with and without clinically meaningful dyspnea at 12 months. Severity of dyspnea and depressive symptoms at 3 months predicted severity of dyspnea at 12 months. CONCLUSIONS: Post-COVID dyspnea is common, persistent, and negatively impacts quality of life. Mood abnormalities may play a causative role in post-COVID dyspnea in addition to potential cardiorespiratory abnormalities. Dyspnea and depression at initial follow-up predict longer-term post-COVID dyspnea, emphasizing that standardized dyspnea and mood assessment following COVID-19 may identify patients at high risk of post-COVID dyspnea and facilitating early and effective management. |
format | Online Article Text |
id | pubmed-10008721 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-100087212023-03-13 Post-COVID dyspnea: prevalence, predictors, and outcomes in a longitudinal, prospective cohort Grewal, Japnam S. Carlsten, Christopher Johnston, James C. Shah, Aditi S. Wong, Alyson W. Ryerson, Christopher J. BMC Pulm Med Research BACKGROUND: The pathophysiology, evolution, and associated outcomes of post-COVID dyspnea remain unknown. The aim of this study was to determine the prevalence, severity, and predictors of dyspnea 12 months following hospitalization for COVID-19, and to describe the respiratory, cardiac, and patient-reported outcomes in patients with post-COVID dyspnea. METHODS: We enrolled a prospective cohort of all adult patients admitted to 2 academic hospitals in Vancouver, Canada with PCR-confirmed SARS-CoV-2 during the first wave of COVID between March and June 2020. Dyspnea was measured 3, 6, and 12 months after initial symptom onset using the University of California San Diego Shortness of Breath Questionnaire. RESULTS: A total of 76 patients were included. Clinically meaningful dyspnea (baseline score > 10 points) was present in 49% of patients at 3 months and 46% at 12 months following COVID-19. Between 3 and 12 months post-COVID-19, 24% patients had a clinically meaningful worsening in their dyspnea, 49% had no meaningful change, and 28% had a clinically meaningful improvement in their dyspnea. There was worse sleep, mood, quality of life, and frailty in patients with clinically meaningful dyspnea at 12 months post-COVID infection compared to patients without dyspnea. There was no difference in PFT findings, troponin, or BNP comparing patients with and without clinically meaningful dyspnea at 12 months. Severity of dyspnea and depressive symptoms at 3 months predicted severity of dyspnea at 12 months. CONCLUSIONS: Post-COVID dyspnea is common, persistent, and negatively impacts quality of life. Mood abnormalities may play a causative role in post-COVID dyspnea in addition to potential cardiorespiratory abnormalities. Dyspnea and depression at initial follow-up predict longer-term post-COVID dyspnea, emphasizing that standardized dyspnea and mood assessment following COVID-19 may identify patients at high risk of post-COVID dyspnea and facilitating early and effective management. BioMed Central 2023-03-13 /pmc/articles/PMC10008721/ /pubmed/36907855 http://dx.doi.org/10.1186/s12890-023-02376-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Grewal, Japnam S. Carlsten, Christopher Johnston, James C. Shah, Aditi S. Wong, Alyson W. Ryerson, Christopher J. Post-COVID dyspnea: prevalence, predictors, and outcomes in a longitudinal, prospective cohort |
title | Post-COVID dyspnea: prevalence, predictors, and outcomes in a longitudinal, prospective cohort |
title_full | Post-COVID dyspnea: prevalence, predictors, and outcomes in a longitudinal, prospective cohort |
title_fullStr | Post-COVID dyspnea: prevalence, predictors, and outcomes in a longitudinal, prospective cohort |
title_full_unstemmed | Post-COVID dyspnea: prevalence, predictors, and outcomes in a longitudinal, prospective cohort |
title_short | Post-COVID dyspnea: prevalence, predictors, and outcomes in a longitudinal, prospective cohort |
title_sort | post-covid dyspnea: prevalence, predictors, and outcomes in a longitudinal, prospective cohort |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008721/ https://www.ncbi.nlm.nih.gov/pubmed/36907855 http://dx.doi.org/10.1186/s12890-023-02376-w |
work_keys_str_mv | AT grewaljapnams postcoviddyspneaprevalencepredictorsandoutcomesinalongitudinalprospectivecohort AT carlstenchristopher postcoviddyspneaprevalencepredictorsandoutcomesinalongitudinalprospectivecohort AT johnstonjamesc postcoviddyspneaprevalencepredictorsandoutcomesinalongitudinalprospectivecohort AT shahaditis postcoviddyspneaprevalencepredictorsandoutcomesinalongitudinalprospectivecohort AT wongalysonw postcoviddyspneaprevalencepredictorsandoutcomesinalongitudinalprospectivecohort AT ryersonchristopherj postcoviddyspneaprevalencepredictorsandoutcomesinalongitudinalprospectivecohort |